FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049202893> ?p ?o ?g. }

• W2049202893 abstract "Mailing Address: Angelo Antunes Salgado • Rua Magalhaes Couto, 237, Apt.101, 20735-180, Meier, Rio de Janeiro RJ Brazil. E-mail: angeloasalgado@gmail.com Manuscript received July, 3rd, 2013; accepted October, 14th, 2013 Introduction With the increased survival of the population, and the widespread use of early detection campaigns, there was a substantial increase in the early detection of several types of neoplasias1. The evolution of cancer treatment, both in relation to chemotherapy as radiotherapy, have not diminished the importance of cardiac monitoring of these patients, since the potentially cardiotoxic drugs usually employed as anthracyclines (doxorubicin, epirubicin, idarubicin) and alkylating agents (cyclophosphamide, ifosphamide) are well know and potentially lethal1,2 The importance of early detection of cardiotoxic action of these drugs, when the suspension can still avoid heart damage and even restore normalcy, is already very well established in echocardiography 1.3. Cardiotoxicity caused by chemotherapy days after infusion, even after several years may occur, demonstrating the importance of long-term cardiac follow-up in these patients, which may be acute, subacute or chronic and characterized mainly by electrocardiographic, myocarditis changes, pericarditis and also by cardiac insufficiency.2 Cardiotoxicity depends on the type of infused agent (anthracyclines with agents that cause more dysfunction), usually occurring more at the extremes of age ( 60 years) in female patients with previous cardiac dysfunction and a history of associated mediastinal radiation. The cumulative dose of the chemotherapeutic agent is directly related to the degree of cardiac injury, being more evident dysfunction with cumulative anthracycline dose above 400mg/m2 and infusion bolus2, 4. The incidence of cardiotoxicity caused by anthracycline ranges from 18% to 26% and may reach 36% in patients receiving cumulative doses above 600mg/m2. In some cases heart failure can occur up to 20 years after the administration of the pharmaceutical drug.5 More recent ly i t has been shown that a new immunomodulatory agent trastuzumab used for the treatment of breast cancer in patients with severe expression of the human epidermal growth factor type 2 (HER-2) receptor may also have damage to cardiomyocytes. Despite the myotoxic effect is unknown, it has the ability to reverse cardiac dysfunction after its suspension, which does not occur with anthracyclines and alkylating agents. However, the use of trastuzumab in patients who have previously made use of anthracyclines, increases the incidence of cardiac disorders 2.5." @default.
• W2049202893 created "2016-06-24" @default.
• W2049202893 creator A5010376229 @default.
• W2049202893 creator A5017643164 @default.
• W2049202893 creator A5076862678 @default.
• W2049202893 date "2014-01-01" @default.
• W2049202893 modified "2023-09-30" @default.
• W2049202893 title "The Role of Echocardiography in Chemotherapy" @default.
• W2049202893 cites W1976210558 @default.
• W2049202893 cites W1980309558 @default.
• W2049202893 cites W1984763397 @default.
• W2049202893 cites W1984797024 @default.
• W2049202893 cites W1997822463 @default.
• W2049202893 cites W2001482375 @default.
• W2049202893 cites W2013605501 @default.
• W2049202893 cites W2076803848 @default.
• W2049202893 cites W2081140676 @default.
• W2049202893 cites W2098766590 @default.
• W2049202893 cites W2115777758 @default.
• W2049202893 cites W2118877196 @default.
• W2049202893 cites W2149445224 @default.
• W2049202893 cites W2167417490 @default.
• W2049202893 cites W2322810385 @default.
• W2049202893 doi "https://doi.org/10.5935/2318-8219.20140004" @default.
• W2049202893 hasPublicationYear "2014" @default.
• W2049202893 type Work @default.
• W2049202893 sameAs 2049202893 @default.
• W2049202893 citedByCount "0" @default.
• W2049202893 crossrefType "journal-article" @default.
• W2049202893 hasAuthorship W2049202893A5010376229 @default.
• W2049202893 hasAuthorship W2049202893A5017643164 @default.
• W2049202893 hasAuthorship W2049202893A5076862678 @default.
• W2049202893 hasBestOaLocation W20492028931 @default.
• W2049202893 hasConcept C126322002 @default.
• W2049202893 hasConcept C164705383 @default.
• W2049202893 hasConcept C2776694085 @default.
• W2049202893 hasConcept C71924100 @default.
• W2049202893 hasConceptScore W2049202893C126322002 @default.
• W2049202893 hasConceptScore W2049202893C164705383 @default.
• W2049202893 hasConceptScore W2049202893C2776694085 @default.
• W2049202893 hasConceptScore W2049202893C71924100 @default.
• W2049202893 hasIssue "1" @default.
• W2049202893 hasLocation W20492028931 @default.
• W2049202893 hasOpenAccess W2049202893 @default.
• W2049202893 hasPrimaryLocation W20492028931 @default.
• W2049202893 hasRelatedWork W2011347913 @default.
• W2049202893 hasRelatedWork W2049397185 @default.
• W2049202893 hasRelatedWork W2073151595 @default.
• W2049202893 hasRelatedWork W2074833529 @default.
• W2049202893 hasRelatedWork W2159512267 @default.
• W2049202893 hasRelatedWork W2304633692 @default.
• W2049202893 hasRelatedWork W2371666691 @default.
• W2049202893 hasRelatedWork W2378355431 @default.
• W2049202893 hasRelatedWork W2399063111 @default.
• W2049202893 hasRelatedWork W3141700921 @default.
• W2049202893 hasVolume "27" @default.
• W2049202893 isParatext "false" @default.
• W2049202893 isRetracted "false" @default.
• W2049202893 magId "2049202893" @default.
• W2049202893 workType "article" @default.